Skip to main content
. 2021 Aug 4;48(4):187. doi: 10.3892/ijmm.2021.5020

Figure 2.

Figure 2

Effects of oxymatrine on NLRP3 inflammasome-mediated pyroptosis in ox-LDL-stimulated HUVECs. HUVECs were pretreated with oxymatrine (4 µM) for 2 h prior to treatment with ox-LDL (100 µg/ml) for 24 h. (A) Western blot analysis for NLRP3 and ASC protein expression. Quantitative analysis for (B) NLRP3/GAPDH and (C) ASC/GAPDH. (D) Western blot analysis for cleaved caspase-1, caspase-1, IL-1β and IL-18 protein expression levels. Quantitative analysis for (E) cleaved caspase-1/caspase-1, (F) IL-1β/GAPDH and (G) IL-18/GAPDH. Data are expressed as the mean ± SD, n=3. *P<0.05, **P<0.01 and NSP>0.05 vs. the control group; #P<0.05 and ##P<0.01 vs. the ox-LDL group. HUVECs were transfected with siNLRP3 or siNC for 24 h, followed by measurement of (H) NLRP3, ASC, cleaved caspase-1, caspase-1, IL-1β and IL-18 protein expression. Data are expressed as the mean ± SD, n=3. *P<0.05, **P<0.01, ***P<0.001 vs. siNC group. Cells were transfected with siNLRP3 or siNC before treatment with oxymatrine (4 µM) for 2 h prior to treatment with ox-LDL (100 µg/ml) for 24 h. Determination of (I) cell viability, (J) LDH release and (K) apoptosis rate. Data are expressed as the mean ± SD, n=3. **P<0.01 vs. the control group; #P<0.05 and ##P<0.01 vs. the ox-LDL + siNC group. OMT, oxymatrine; ox-LDL, oxidized low-density lipoprotein; NS, no statistical significance; siNLRP3, small interfering ribonucleic acid (siRNA) for NLRP3; siNC, siRNA for negative control; HUVECs, human umbilical vein endothelial cells; LDH, lactate dehydrogenase; NLRP3, NLR family pyrin domain containing 3; ASC, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain; Cleaved cas-1, Cleaved caspase-1.